Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Hepatitis B Vaccine Market Outlook

The hepatitis B vaccine market size in the 7 major markets was valued at USD 4.8 billion in 2023, driven by the increasing incidence of hepatitis B cases across the major markets. The market is expected to grow at a CAGR of 4.8% during the forecast period of 2024-2032, with the values likely to rise from USD 5 billion in 2024 to USD 7.3 billion by 2032.

Hepatitis B Vaccine: Introduction

Hepatitis B is a liver infection caused by the hepatitis B virus. The infection may be long term (chronic) or short term (acute). Chronic hepatitis B can put people at the risk of death from cirrhosis and liver cancer. It can spread through fluid transfusion from an infected person and even transfer from a mother to the child. Hepatitis B vaccinations play a crucial role in minimizing the risk of this fatal disease. The vaccinations can protect against the infection for at least 20 years.

Hepatitis B Vaccine Market Analysis

With notable advancements within the range vaccines available, the hepatitis B vaccine market value has risen significantly in the recent years. Some of the notable authorized hepatis B vaccinations include Engerix-B, a noninfectious recombinant DNA vaccine, Heplisav-B®, Recombivax HB, and Twinrix hepatitis vaccine, which is indicated for both hepatitis A and B, adding versatility to the market.

The hepatitis B vaccine market growth is likely to expediate with the on-going investigations. The U.S. CDC's initiative for Universal Hepatitis B Vaccination in Adults aged 19–59 signals a broader adoption trend. VTP-300, the hepatits B vaccination by Vaccitech is undergoing trials and has shown positive outcomes, indicating its breakthrough in upcoming years.


 
GSK plc's upcoming presentation at The Liver Meeting® 2023 is set to unveil insights from the B-Together phase IIb trial on bepirovirsen. It is an antisense oligonucleotide for chronic hepatitis B showcasing encouraging outcomes, especially in combination with pegylated interferon alfa. The trial evaluates the sequential regimen's efficacy in treating CHB infection, reducing hepatitis B surface antigen, and lowering virus DNA in the blood. Such developments hold a promising future for the vaccinations market in the forecast period.

Hepatitis B Vaccine Market Segmentation

Market Breakup by Type

  • Single Antigen
  • Combination

Market Breakup by Age

  • Pediatrics
  • Adults

Market Breakup by End User

  • Hospitals
  • Clinics
  • Vaccination Centres
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Hepatitis B Vaccine Market Overview

The World Health Organization estimates that the world population may suffer with 1.5 million new hepatitis B infections every year, as a result, the hepatitis B vaccine market demand has increased significantly. North America, particularly the United States, has dominated the market in the historical period. The market share can be accredited to the presence of key market players offering advanced vaccines. The region's well-established healthcare infrastructure and high awareness levels have further propelled market growth.

European market has also expanded with its robust healthcare system and proactive vaccination drives. The ongoing research and development activities by pharmaceutical companies, along with collaborations and partnerships among research institutions, continue to drive innovation in the region.

Going forward, Asia Pacific and Africa are poised to become pivotal centres for hepatitis B vaccine market share. These regions face a higher burden of hepatitis B infections, demanding high vaccination initiatives. Asia Pacific, being home to densely populated countries with emerging economies, is witnessing a surge in healthcare awareness and infrastructure development. The rising prevalence of hepatitis B in these regions amplifies the urgency for vaccination programs.

Hepatitis B Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Merck & Co., Inc.
  • Sanofi S.A. 
  • Dynavax Technologies Corporation 
  • GlaxoSmithKline plc. 
  • Pancea Biotech Ltd 
  • Beijing Tiantan Biological Products Co., Ltd. 
  • VBI Vaccines Inc. 
  • Emmy Vaccine Co. Ltd. 
  • Beijing Minhai Biological Technology Co., Ltd.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Age
  • End User
  • Region
Breakup by Type
  • Single Antigen
  • Combination
Breakup by Age
  • Pediatrics
  • Adults
Breakup by End User
  • Hospitals
  • Clinics
  • Vaccination Centres 
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Merck & Co.,Inc
  • Sanofi S.A.
  • Dynavax Technologies Corporation
  • GlaxoSmithKline plc.
  • Pancea Biotech Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • VBI Vaccines Inc.
  • Emmy Vaccine Co.,Ltd.
  • Beijing Minhai Biological Technology Co., Ltd.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market attained a value of about USD 4.8 billion in 2023, driven by the increasing prevalence of hepatitis B cases across the7 major markets.

The market is anticipated to grow at a CAGR of 4.8% during the forecast period of 2024-2032, likely to reach a market value of USD 7.3 billion by 2032.

The market demand has increased with the advent of highly efficient vaccinations such as Engerix-B, Heplisav-B®, Recombivax HB, and Twinrix hepatitis vaccine.

The current market trend is marked by the ongoing investigation on vaccines for adults falling the age group of 19-59. One such example is VTP-300 by Vaccitech, which is currently in trials and displayed positive results.

Single antigen and combination are common Hepatitis B vaccine types. 

They are available for pediatrics as well as adults.

Major end users include hospitals, clinics, and vaccination centres. 

The major regions of the market include United States, EU-4 and the United Kingdom, Japan. EU-4 includes Germany, France, Italy, and Spain.

Key players involved in the market are Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc., Pancea Biotech Ltd., Beijing Tiantan Biological Products Co., Ltd., VBI Vaccines Inc., Emmy Vaccine Co. Ltd., Beijing Minhai Biological Technology Co., Ltd., and Dynavax Technologies Corporation.

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Strategic Solutions for Informed Decision-Making

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-120-433-0800

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124